Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Morphotek
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed adenocarcinoma of the lung classified as stage IV
Confirmed folate receptor-alpha (FRA) expression by immunohistochemistry (IHC)
Measurable disease with at least one unidimensionally measurable lesion according to RECIST criteria version 1.1 by computed tomography (CT) or magnetic resonance imaging (MRI) scans (CT or MRI scans must have been performed within 30 days prior to the first dose of farletuzumab or placebo)
Must have received no prior chemotherapy, radiation therapy or surgery with curative intent for adenocarcinoma of the lung
You may not be if
Participants who have had previous chemotherapy for adenocarcinoma of the lung
Prior surgery with curative intent for adenocarcinoma of the lung
Prior radiotherapy for adenocarcinoma of the lung. (Prior treatment with local radiotherapy for symptom control \[i.e., palliative radiation with non-curative intent\] is permitted)
